Creatinine Test Market

The Creatinine Test Market is valued at USD 1.7 Bn in 2026 and is projected to reach USD 6 Bn, growing at a CAGR of 20% by 2033.

Growing Prevalence of Kidney Diseases Coupled with Rising Diabetic Population Will Drive Market

Although creatinine is required by the body in moderate quantities, high creatinine levels are potentially harmful for the body, especially for the kidneys and may cause a lot of complications. Elevated creatinine levels typically account for tiredness, fatigue, weakness, dehydration, and confused behaviour. In a lot of cases, there may not be any visible symptoms of having severe kidney problems or having a high creatinine level in the blood. Only a routine blood test might reveal the excess of creatinine. This is expected to predominantly drive the growth of creatinine test market worldwide. Rising incidence of renal disorders/diseases, increased usage of point-of-care diagnostics, and rising prevalence of chronic ailments are driving the growth of the global creatinine test market. Factors such as market participant investments, increased R&D efforts, the high prevalence of kidney disorders, and expanding government initiatives are projected to fuel market expansion significantly.

The high frequency of renal diseases is a primary driving factor for the expansion of creatinine test market. Such situations, including various kidney treatments, necessitate continuous monitoring of components such as creatinine and albumin, and their ratios, for which different urine analysis products and procedures are employed. Chronic kidney disease (CKD) is a degenerative disorder that affects more than 10% of the global population, or more than 800 million people. As a result, the rising prevalence of renal illnesses will also be an important factor pushing the growth prospects of creatinine test market.

Another factor that increases the risk of contracting chronic kidney disease is the growing prevalence of diabetes. The primary cause of the rising diabetes prevalence are factors such as obesity, age, ethnicity, lifestyle, socioeconomic level, education, and urbanisation. Diabetes can damage blood arteries in the kidneys as well as nephrons, causing them not to function as well as they should, causing kidney damage. Diabetes will affect approximately 537 million persons aged 20 to 79 in 2021. The global diabetic population is estimated to reach 643 million by 2030 and 783 million by 2045. Diabetes patients are more likely to have CKD. One in every three diabetic adults has CKD. The continual increase in diabetic patients will propel the creatinine test market in the coming years.

Urinary Tract Obstruction Will Dominate Market with Rising Kidney Disorders

In the forecast period, the urinary tract obstruction segment will have the highest revenue share of any application segment in global creatinine test market. The increasing prevalence of kidney stones due to changing lifestyles propels the international urinary tract obstruction segment forward. Rising cancer and postoperative infection prevalence in kidney transplant recipients move the urinary tract obstruction sector forward. The increased prevalence of hydronephrosis in the population will drive the demand for urinary tract obstruction throughout the predicted period. The growing number of catheter and stent manufacturers and distributors for urinary tract obstruction is expanding the regional availability of the goods in underserved areas and boosting the market for urinary tract obstruction.

The US Remains Spearheading Region on the Back of Mounting R&D Investments

North America is expected to lead the creatinine test market in the forecast period. Significant healthcare expenditure, rising prevalence of various renal ailments, substantial presence of market players, and the usage of advanced technology in new product development are some factors driving creatinine test market growth in this area. Another aspect driving the market growth is favourable reimbursement policies. Government efforts to raise awareness and encourage better therapeutic approaches for diagnostics and medical insurance will assist North America in maintaining its market dominance during the projection period. The United States has the most significant proportion of the North American regional market. The local presence of essential market players and the easy availability of technologically advanced items contribute to its dominance. Rising R&D initiatives to create novel products will likely drive market expansion significantly during the forecast period. More than one in seven, or 15% of US adults, or 37 million people, is projected to have CKD. The growing cases of CKD in the nation will help the regional market flourish in the coming years.

Asia Pacific is expected to be the fastest-growing market because of the increasing desire for early diagnosis, constantly developing technology, and the availability of a large patient pool. The government's attempts to control chronic renal illnesses also encourage market growth. Rising knowledge about creatinine testing methods, an aging population suffering from chronic diseases such as diabetes and renal problems, and increased R&D efforts in the healthcare industry are some of the other main reasons driving the market's rapid revenue growth in the Asia Pacific. According to the first Longitudinal Ageing Study in India (LASI) announced by the Union Ministry of Family and Health Welfare on January 6, 2020, in India, two out of every three older adults have a chronic illness. The country's growing number of chronic diseases, the regional market will thus propel in the coming years.

Market participants launch new goods and forge collaborations, alliances, and partnership agreements. In July 2020, Sysmex Corporation announced that Siemens Healthcare Diagnostics Inc. and Sysmex America, Inc, a Sysmex subsidiary in the United States, signed a distribution agreement that grants Sysmex America the exclusive right to distribute Siemens' urine chemistry analysers, and reagents for hospital and reference laboratory use in the North American market, to boost Sysmex's urinalysis business in North America. In January 2020, SphingoTec GmbH, located in Germany, introduced the IB10 sphingotest pencil, a Point-of-Care (POC) test for Proenkephalin (pencil). This biomarker allows for real-time monitoring of kidney function using a standard blood test.

A few of the creatinine test market players include:

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Beckman Coulter (Danaher Corporation)
• bioMérieux S.A.
• Ortho Clinical Diagnostics
• Sysmex Corporation
• DiaSorin S.p.A.
• Agilent Technologies, Inc.
• PerkinElmer, Inc.
• Bio Rad Laboratories, Inc.
• Tosoh Corporation
• Eurofins Scientific
• Quidel Corporation

Global Creatinine Test Market is Segmented as Below:

By Test Type

• Blood Test
• Urine Test
• Others

By Product

• Consumables
• Instruments

By Application

• Urinary Tract Obstruction
• Renal Failure
• Kidney Cancer
• Glomerulonephritis
• Others

By End Use

• Hospital and Clinics
• Diagnostic Centre
• Research Institutes

By Region

• North America
• Europe
• Asia Pacific
• LAMEA